A Nasal Spray For Depression? FDA Gives Its Approval
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first standalone therapy for adults suffering from major depressive disorder (MDD) who have not responded adequately to at least two oral antidepressants.
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback